A clinical evaluation of Tazobactam/Piperacillin (TAZ/PIPC) in otorhinolaryngological infections

Abstract

Otorhinolaryngological clinical infections were conducted on Tazobactam/Piperacillin (TAZ/PIPC), in which Tazobactam (TAZ), a novel β-lactamase inhibitor was combined, on patients with otitis media sinusitis, tonsillitis, peritonsillitis and peritonsillar abscess. Among the 159 cases administered TAZ/PIPC, 139 cases were found to be evaluable for its clinical efficacy and included 36 cases with otitis media, 32 cases with sinusitis, 33 cases with tonsillitis and 38 cases with peritonsillitis-peritonsillar abscess, respectively. The clinical efficacies against each disease were as follows: otitis media 75%, sinusitis 91%, tonsillitis 91% and peritonsillitis-peritonsillar abscess 92%, respectively. In the case of monomicrobial infection, the bacteriological responses against gram-positive bacteria, gram negative bacteria and anaerobic bacteria were 95%, 87% and 100%, respectively, while in the case of polymicrobial infection it was 94%, with an overall response of 94.3%. The overall bacteriological response against each strain was 96.0% while it was 91.2% against g-lactamase producing strains. Adverse events were observed in 7 out of 156 cases (4.5%). Abnormal laboratory findings were observed in 13 out of 137 cases (9.5%). Based on the above findings, Tazobactam/Piperacillin (TAZ/PIPC) is thus considered to be highly useful in the treatment of otorhinolaryngological infections.